Trump directed a panel headed by HHS Secretary Robert F. Kennedy Jr. to assess “the prevalence of and threat” posed by SSRIs, ...

As Vitality becomes the first UK insurance provider to offer discounted weight-loss jab treatment, Yahoo UK spoke to them to ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Until now, the drugs have only been available from specialist NHS clinics or private pharmacies, costing around £150 to £200 ...

Customers are to be offered discounted weight loss treatments through insurance giant Vitality in a UK first. The group, ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

This includes U.S. direct-to-consumer advertising on Zepbound and Mounjaro and U.S. launch activities for Kisunla and Ebglyss. We also increased our commercial investment outside the U.S. to ...

Obviously, we will follow how Mounjaro and KwikPen gets adopted in ... where we manufacture products for companies that already have a commercial presence or frankly distribute products that ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...